Tresiba Travel & Timezone-Shift Protocols: The Complete Clinical Guide

Why Insulin Degludec Behaves Differently From Other Basal Insulins During Travel

Insulin degludec's pharmacokinetic profile sets it apart from every other basal insulin currently approved in the United States. Its ultra-long, flat action curve means a single missed or shifted dose does not produce the sharp glycemic swings seen with insulin glargine U-100 or insulin detemir. Understanding this pharmacology is the starting point for any travel protocol.

The Pharmacokinetic Basis for Timing Flexibility

After subcutaneous injection, degludec forms soluble multihexamer chains at the injection site. These chains dissociate slowly and continuously, releasing monomers into the circulation at a near-constant rate. The result is a half-life of roughly 25 hours and a duration of action that exceeds 42 hours in most patients. FDA prescribing information for Tresiba confirms the >42-hour duration and the approved ±8-hour dosing window. [1]

Because steady state is not reached until 2 to 3 days of consecutive dosing, a traveler who shifts injection time once does not immediately destabilize their 24-hour glucose profile. PK/PD data from Heise et al. (Diabetes Care, 2012) demonstrated that degludec's day-to-day variability is four times lower than glargine U-100. [2]

How the ±8-Hour Window Was Established

The ±8-hour flexibility comes from a dedicated crossover pharmacodynamic study. Investigators measured glucose infusion rates (GIR) when degludec was dosed at intervals ranging from 8 to 40 hours. Glucose-lowering effect remained stable across all intervals tested, confirming that the drug tolerates substantial schedule deviation without meaningful loss of coverage. The primary PD flexibility data appear in Mathieu et al. (Diabetes Care, 2014). [3]

That 8-hour buffer maps well onto real-world travel. A traveler flying from New York to London crosses 5 time zones eastward; a New York-to-Los-Angeles flight crosses 3 time zones westward. Both scenarios fall within the ±8-hour window, meaning most transatlantic and domestic US flights require no dose adjustment at all beyond shifting to local time.

The DEVOTE Trial: What It Tells Travelers About Hypoglycemia Risk

DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events) enrolled 7,637 patients with type 2 diabetes and established cardiovascular disease or multiple CV risk factors. The trial ran for a median of 2.0 years and compared degludec U-100 against glargine U-100, both titrated to a fasting glucose target of 71 to 90 mg/dL (4.0 to 5.0 mmol/L). Full results were published in the New England Journal of Medicine in 2017. [4]

Cardiovascular Safety Findings

Degludec was non-inferior to glargine for major adverse cardiovascular events (MACE): the rate ratio was 0.91 (95% CI 0.78 to 1.06), meeting the pre-specified non-inferiority margin. [4] For travelers managing comorbid heart disease, this means switching from glargine to degludec before a long trip does not introduce new cardiovascular risk.

Hypoglycemia Data Relevant to Travel

Nocturnal hypoglycemia occurred at a rate 36% lower with degludec than with glargine (rate ratio 0.64, 95% CI 0.48 to 0.86, P<0.001). [4] Severe hypoglycemia was also significantly lower (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001). [4]

These figures matter for travel because hypoglycemia risk is already elevated when routine schedules break down. Disrupted meal timing, unfamiliar cuisine, altered activity levels, and jet lag all shift glucose dynamics unpredictably. A basal insulin that delivers 36% fewer nocturnal hypoglycemic events at baseline provides meaningful added safety during those disruptions. ADA Standards of Care in Diabetes 2024 cite lower hypoglycemia risk as a reason to prefer degludec or glargine U-300 for patients at elevated hypoglycemia risk. [5]

Eastward Travel: Shortening the Dosing Interval

Flying east shortens the calendar day. A traveler departing New York at 10:00 PM and landing in Paris 7 hours later arrives at 5:00 AM Paris time, but only 7 hours have elapsed physiologically. If their usual degludec injection is at 10:00 PM local time, they now face the question of whether to dose at Paris 10:00 PM (20 hours after departure) or to wait until the next night.

Practical Rule for Eastward Flights

The simplest protocol: take the usual dose at the usual local time in the destination time zone on arrival day, provided the resulting interval is no shorter than 8 hours from the previous dose. Because DEVOTE titrated to aggressive fasting targets and still showed lower severe hypoglycemia, conservative titration during the travel window is appropriate. [5]

For extreme eastward crossings (9 or more time zones, such as New York to Tokyo), the interval from the last home-time dose to the first destination-time dose could drop below 8 hours. In that case:

1. Administer the last home dose at the usual home time before departure.
2. Skip the in-flight dose entirely.
3. Resume at the destination local time the following evening, producing a single extended interval of up to 32 to 36 hours.

Because degludec's duration exceeds 42 hours, coverage is maintained across this extended interval. Heise et al. (2016) confirmed that glucose-lowering effect persists through 40-hour dosing intervals with no rebound hyperglycemia. [6]

Blood Glucose Monitoring During Eastward Transitions

Check fasting glucose every morning for 3 days after arrival. Steady state with the new time-zone schedule is reached within that window. The ADA recommends self-monitoring at least twice daily during any basal insulin dose adjustment period. [5] Carry rapid-acting insulin and a glucagon kit; do not rely solely on the basal-only protocol for correction.

Westward Travel: Lengthening the Dosing Interval

Westward flights lengthen the calendar day. A traveler flying from London to Los Angeles on a 10-hour flight departs at noon and lands at 2:00 PM local time, but the destination clock reads 6:00 AM. Their usual 10:00 PM dose now lands 22 hours after the last dose if they wait until LA local 10:00 PM.

22 hours is well within the approved interval range, and no adjustment is needed beyond resuming at local destination time. Even the most extreme westward crossing (London to Auckland, approximately 13 time zones) produces a dosing interval of roughly 35 hours. Degludec's >42-hour duration covers that interval without a mid-flight supplemental dose. [1]

When a Supplemental Dose May Be Warranted

Westward travel rarely requires dose adjustment. The exception is a traveler whose pre-travel A1c is poorly controlled (above 9%) and who is already running fasting glucose values consistently above 200 mg/dL. In that scenario, the extended interval may produce symptomatic hyperglycemia. The Endocrine Society Clinical Practice Guideline on Insulin Therapy recommends individualized dosing decisions for patients with A1c above 9% undergoing schedule changes. [7]

For most well-controlled patients, westward travel with degludec requires nothing more than resuming injections at local time after landing.

Storage During Transit: Temperature, TSA Rules, and Pack Strategy

Insulin degludec is not heat-stable indefinitely. The FDA-approved storage parameters matter more during travel than at home because luggage temperature can swing dramatically. Full storage requirements appear in the Tresiba prescribing information. [1]

Temperature Limits and the 56-Day Rule

Unopened Tresiba pens must be refrigerated at 36 to 46°F (2 to 8°C) until first use. Once in use (or stored at room temperature from the start), the pen may be kept at room temperature below 86°F (30°C) for up to 56 days. After 56 days, discard the pen regardless of remaining units.

This means a traveler on a 3-week trip does not need to refrigerate the active pen at all, provided ambient temperatures stay below 86°F. For travel to hot climates (Southeast Asia, Middle East, Sub-Saharan Africa), an insulated insulin wallet with a reusable gel pack is appropriate. Insulin thermal degradation studies demonstrate that storage at temperatures exceeding 37°C accelerates fibril formation and reduces potency. [8]

Never store insulin in checked baggage. Cargo holds on commercial aircraft regularly reach temperatures below freezing at cruising altitude, and frozen insulin loses potency. Carry all pens in a personal item that stays in the cabin.

TSA and International Customs

The TSA explicitly permits insulin, syringes, and lancets in carry-on bags without a doctor's note, though a pharmacy label on the pen is recommended. TSA medical condition guidelines are published at tsa.gov. [9] International travelers should carry a brief letter from their prescriber on letterhead, listing medication names, doses, and the medical necessity. Many countries require this for controlled or injectable medications at customs.

Carry at least twice the expected supply. Lost luggage, extended layovers, and customs delays can leave a traveler without insulin for 24 to 48 hours.

Jet Lag, Circadian Disruption, and Glucose Physiology

Jet lag is not merely an inconvenience for people with diabetes. It represents a genuine circadian disruption that alters cortisol secretion, growth hormone pulsatility, and hepatic glucose output, all of which affect fasting glucose independent of insulin dose. Scheer et al. (PNAS, 2009) demonstrated that circadian misalignment alone increased postprandial glucose by 6% and decreased insulin sensitivity by 17% in healthy subjects. [10]

Practical Management of Jet-Lag Hyperglycemia

Travelers with type 1 diabetes on a basal-bolus regimen may need to increase their correction factor for 48 to 72 hours after a major timezone crossing. Those with type 2 diabetes on degludec alone (no bolus insulin) should check fasting and 2-hour postprandial glucose for the first 3 days and contact their care team if fasting values exceed 180 mg/dL on two consecutive mornings.

Melatonin 0.5 to 5 mg taken at the destination bedtime may shorten time to circadian re-entrainment. A meta-analysis in the Cochrane Database (Herxheimer & Petrie, 2002) found melatonin more effective than placebo for jet-lag symptom reduction when crossing 5 or more time zones. [11] Clinicians should note that melatonin has no direct effect on insulin sensitivity, but better sleep reduces cortisol, which reduces fasting glucose.

Alcohol, Altitude, and Physical Activity

Long-haul flights typically involve altered eating, alcohol consumption, and prolonged immobility followed by sudden increased walking (airport transfers, sightseeing). Each variable shifts glucose independently:

Alcohol inhibits hepatic gluconeogenesis and can potentiate hypoglycemia for up to 24 hours after consumption. The ADA position statement on alcohol and diabetes recommends eating carbohydrate with any alcoholic drink and checking glucose before bed. [5]

High altitude (above 8,000 feet / 2,438 meters, common in cities like La Paz, Bolivia or Lhasa, Tibet) reduces partial pressure of oxygen, which alters erythrocyte metabolism and can produce falsely low fingerstick glucose readings with some glucometer systems. Gribble et al. Documented altitude-related glucometer inaccuracy in Diabetes Care (2014). [12] Consider a continuous glucose monitor (CGM) as the primary monitoring tool for high-altitude destinations.

Type 1 vs. Type 2 Diabetes: Protocol Differences

The ±8-hour flexibility applies to both T1D and T2D, but the risk profiles differ. People with type 1 diabetes have no endogenous insulin reserve, so a missed or incorrectly timed degludec dose produces faster glycemic deterioration. People with type 2 diabetes retain some beta-cell function and hepatic glucose buffering. The DEVOTE trial enrolled only T2D patients; T1D travel data come primarily from the BEGIN series of trials. [4]

Type 1 Diabetes Travel Protocol

Patients with T1D should:

• Never allow the dosing interval to exceed 40 hours without contacting a clinician.
• Carry a glucagon emergency kit (nasal or injectable) and ensure a travel companion knows how to use it.
• Use a CGM with low-glucose alarms enabled throughout the trip.
• Pre-book a diabetes care contact in the destination country through the International Diabetes Federation directory.

The International Diabetes Federation maintains a global directory of diabetes associations at idf.org, which can be used to locate emergency care. [13]

Type 2 Diabetes Travel Protocol

Patients with T2D on degludec alone (no bolus insulin) have more physiological buffer. The primary risks are hyperglycemia from schedule disruption and meal composition changes rather than severe hypoglycemia. Patients on degludec plus a GLP-1 receptor agonist should be aware that GLP-1 agents (liraglutide, semaglutide) slow gastric emptying, which can amplify nausea during turbulence. Dose the GLP-1 agent at the same local time in the destination as at home, exactly as with degludec.

Pre-Travel Checklist for Patients and Prescribers

A structured pre-travel consultation at least 2 weeks before departure allows time to adjust doses, update prescriptions, and address destination-specific risks. The following framework organizes the key steps.

At Least 2 Weeks Before Departure

• Review current A1c and fasting glucose trend. If A1c exceeds 8.5%, consider whether travel timing should be deferred or whether bolus insulin supplementation is needed.
• Confirm the total number of time zones crossed and calculate whether the first destination-time dose will fall within the ±8-hour window.
• Prescribe at least twice the supply needed for the trip duration.
• Write a travel letter on letterhead: patient name, medication name (insulin degludec), concentration (U-100 or U-200), dose, and diagnosis.
• Update the glucagon prescription. Nasal glucagon (Baqsimi 3 mg) is approved by the FDA as a needle-free option. [14]

At the Time of Packing

• Place all insulin pens in a labeled, insulated pouch in carry-on luggage.
• Pack a printed copy of the dose-adjustment protocol (eastward vs. Westward, interval limits).
• Verify that the CGM transmitter, receiver, and at least 14 days of sensors are packed.
• Include 15-gram fast-acting carbohydrate (glucose tablets or gel) in a pocket-accessible location.

On Arrival

• Administer the first destination-time dose at local 10:00 PM (or the patient's preferred evening time) on arrival day, provided at least 8 hours have elapsed since the previous dose.
• Check fasting glucose on days 1, 2, and 3 post-arrival and adjust bolus (if applicable) before basal.
• Titrate the degludec dose upward only if fasting glucose exceeds 160 mg/dL on two consecutive mornings after 3 days of stable local dosing. ADA titration guidance recommends 2-unit increases every 3 days for basal insulin until fasting target is reached. [5]

Special Populations: Renal Impairment, Elderly Travelers, Pregnancy

Renal Impairment

Degludec is primarily cleared by proteolytic degradation rather than renal excretion, but reduced renal function still increases hypoglycemia risk by reducing gluconeogenic substrate availability. The FDA label notes that patients with renal impairment may require more frequent glucose monitoring. [1] For travelers with eGFR below 30 mL/min/1.73m², reduce the starting degludec dose by 20% before travel and monitor glucose twice daily.

Elderly Travelers

Adults over 75 are at higher baseline risk for severe hypoglycemia due to impaired hypoglycemia awareness, reduced renal reserve, and polypharmacy. The American Geriatrics Society Beers Criteria recommends avoiding sliding-scale insulin in older adults and favors basal-only or basal-bolus regimens with individualized targets. [15] For elderly travelers on degludec, an A1c target of 7.5 to 8.0% is acceptable, and the fasting glucose target during travel may be relaxed to 100 to 140 mg/dL to reduce hypoglycemia risk.

Pregnancy

Insulin degludec is FDA Pregnancy Category B (former classification) with limited human data. The EXPECT trial (Mathiesen et al., Diabetes Care, 2012) compared degludec with detemir in pregnant women with type 1 diabetes and found comparable maternal and neonatal outcomes. [16] Pregnant travelers should not self-adjust degludec doses without direct clinician guidance, and travel beyond 32 weeks gestation requires clearance from both the obstetrician and the diabetes care team.

Switching From Glargine or Detemir Before Travel

Some clinicians proactively switch high-travel patients to degludec before a major trip specifically to gain the ±8-hour flexibility. The switch is unit-for-unit from glargine U-100 or detemir. FDA prescribing information confirms that patients may convert from any basal insulin to degludec at the same total daily dose. [1]

Allow at least 2 to 3 days of stable dosing at home before travel to reach steady state and confirm the fasting glucose response. A pre-travel switch made 3 days before departure is too late to verify tolerability. Schedule the switch at minimum 2 weeks before departure.

Patients converting from insulin glargine U-300 (Toujeo) may need a 10 to 20% dose increase at conversion, because glargine U-300 is slightly less bioavailable than degludec at equal unit doses. Bajaj et al. (Diabetes Care, 2017) compared U-300 glargine and degludec head-to-head and found degludec produced modestly lower fasting glucose at similar hypoglycemia rates. [17]

Monitoring Technology on the Road

Continuous Glucose Monitors

CGM devices approved in the US (Dexacom G7, FreeStyle Libre 3, Medtronic Guardian 4) all function at standard commercial aircraft cabin altitudes (6,000 to 8,000 feet pressurized). Most sensors are not affected by airport security X-ray or millimeter-wave scanners, but patients should request a manual pat-down rather than walking through the Advanced Imaging Technology (AIT) scanner as a precaution. Dexacom's official guidance recommends not exposing sensors to direct X-ray radiation, a position consistent with FDA clearance documents. [18]

Fingerstick Backup

Every CGM can fail. Carry a fingerstick meter with at least 50 test strips regardless of CGM reliance. At high altitude (above 8,000 feet / 2,438 meters), use a meter validated for altitude accuracy; the Contour Next series has published altitude validation data. [12]